CRYSTALLINE FORMS OF AN ORALLY AVAILABLE, SELECTIVE KIT AND PDGFR KINASE INHIBITOR
The present invention relates to crystalline avapritinib, polymorphs and hydrates thereof as well as to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising crystalline avapritinib and at least one pharmaceutically acceptable excipient. The p...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French German |
Published |
18.05.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to crystalline avapritinib, polymorphs and hydrates thereof as well as to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising crystalline avapritinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of patients with gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematologic neoplasm (SM- AHN) and mast cell leukemia (MCL). |
---|---|
Bibliography: | Application Number: EP20200735402 |